BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 14619251)

  • 21. What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation.
    Mullahy J
    Med Care; 1996 Dec; 34(12 Suppl):DS124-35. PubMed ID: 8969321
    [No Abstract]   [Full Text] [Related]  

  • 22. What decision-makers want and what they have been getting.
    McGregor M
    Value Health; 2006; 9(3):181-5. PubMed ID: 16689712
    [No Abstract]   [Full Text] [Related]  

  • 23. Pre-assessment to assess the match between cost-effectiveness results and decision makers' information needs: an illustration using two cases in rehabilitation medicine in The Netherlands.
    IJzerman MJ; Reuzel RP; Severens HL
    Int J Technol Assess Health Care; 2003; 19(1):17-27. PubMed ID: 12701936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subgroup analyses in cost-effectiveness analyses to support health technology assessments.
    Fletcher C; Chuang-Stein C; Paget MA; Reid C; Hawkins N
    Pharm Stat; 2014; 13(4):265-74. PubMed ID: 24931490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 26. Regarding probabilistic analysis and computationally expensive models: necessary and required?
    Caro JJ; Getsios D; Möller J
    Value Health; 2007; 10(4):317-8; author reply 319. PubMed ID: 17645686
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-effectiveness acceptability curves--caveats quantified.
    Jakubczyk M; Kamiński B
    Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies.
    Claxton K
    J Health Econ; 1999 Jun; 18(3):341-64. PubMed ID: 10537899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of economic appraisal in Denmark.
    Alban A
    Soc Sci Med; 1994 Jun; 38(12):1647-52. PubMed ID: 8047923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The need for economic evaluation of telemedicine to evolve: the experience in Alberta, Canada.
    Hailey D; Jennett P
    Telemed J E Health; 2004; 10(1):71-6. PubMed ID: 15104918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical technology meets managed competition.
    Durenberger D; Foote SB
    J Am Health Policy; 1993; 3(3):23-8. PubMed ID: 10125731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stochastic league tables: communicating cost-effectiveness results to decision-makers.
    Hutubessy RC; Baltussen RM; Evans DB; Barendregt JJ; Murray CJ
    Health Econ; 2001 Jul; 10(5):473-7. PubMed ID: 11466807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Life-cycle management: a long-term challenge.
    Newman C
    Med Device Technol; 2003 Apr; 14(3):32-3. PubMed ID: 12789698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence isn't everything. Even the best purchasing practices vulnerable.
    DoBias M
    Mod Healthc; 2007 Apr; 37(17):32-3. PubMed ID: 17477202
    [No Abstract]   [Full Text] [Related]  

  • 35. Technology assessment and coverage decision making.
    McGivney WT
    AAPPO J; 1994; 4(5):11-2, 14-7. PubMed ID: 10150666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Industry sponsored bias in cost effectiveness analyses.
    John-Baptiste A; Bell C
    BMJ; 2010 Oct; 341():c5350. PubMed ID: 20943724
    [No Abstract]   [Full Text] [Related]  

  • 38. NICE's use of cost effectiveness as an exemplar of a deliberative process.
    Culyer AJ
    Health Econ Policy Law; 2006 Jul; 1(Pt 3):299-318. PubMed ID: 18634698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breaking up is hard to do: why disinvestment in medical technology is harder than investment.
    Haas M; Hall J; Viney R; Gallego G
    Aust Health Rev; 2012 May; 36(2):148-52. PubMed ID: 22624634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Introducing new mechanical ventilation technology: the hospital perspective.
    Kacmarek RM
    Respir Care; 1995 Sep; 40(9):947-51. PubMed ID: 10152238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.